New article published: Vera et al, 2024

Congratulations to Prof. Zalcman and colleagues on the publication of their article on the activity and safety of a booster dose of radiotherapy in patients with non-small-cell lung cancer in the Lancet Oncology journal. We are delighted to have contributed to the success of this article!

𝐍𝐨𝐧-𝐬𝐦𝐚𝐥𝐥 𝐜𝐞𝐥𝐥 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 (NSCLC) accounts for 80% of all lung cancers. They are adenocarcinomas in 65% of cases and squamous cell carcinomas in 20%. 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐩𝐭𝐢𝐨𝐧𝐬 depend on stage and the patient's overall condition. In stage III patients, the options are chemoradiotherapy, radiotherapy, surgery or more targeted treatments. However, the 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐨𝐫𝐚𝐜𝐢𝐜 𝐫𝐚𝐝𝐢𝐚𝐭𝐢𝐨𝐧𝐬 is controversial in stage III patients.

The aim was therefore to evaluate the 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐚𝐧𝐝 𝐝𝐨𝐬𝐞 𝐬𝐚𝐟𝐞𝐭𝐲 𝐨𝐟 𝐜𝐨𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐫𝐲 𝐫𝐚𝐝𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 up to 74 Gy compared with standard radiotherapy (66 Gy). A total of 158 patients took part in the clinical trial. The 𝐫𝐚𝐭𝐞 𝐨𝐟 𝐥𝐨𝐜𝐚𝐥 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 at 15 months 𝐰𝐚𝐬 𝐡𝐢𝐠𝐡𝐞𝐫 in the complementary radiotherapy group, while the proportion of grade 3-4 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐰𝐚𝐬 𝐥𝐨𝐰𝐞𝐫 than in the control group, although non-significantly different.

These promising results underline the need for a 𝐫𝐚𝐧𝐝𝐨𝐦𝐢𝐳𝐞𝐝 𝐩𝐡𝐚𝐬𝐞 𝟑 𝐭𝐫𝐢𝐚𝐥 evaluating the effect of adjuvant radiotherapy in patients with stage 3 NSCLC. The article is already available on the journal's website! 𝐃𝐎𝐈: 𝟏𝟎.𝟏𝟎𝟏𝟔/𝐒𝟏𝟒𝟕𝟎-𝟐𝟎𝟒𝟓(𝟐𝟒)𝟎𝟎𝟑𝟐𝟎-𝟔